[A26-67] Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-67
Commission:
Commission awarded on 01.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children during their first respiratory syncytial virus (RSV) season with an indication for secondary prevention of lower respiratory tract infections caused by RSV
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-67